BioCentury
ARTICLE | Clinical News

Merimepodib: Discontinuing development

October 10, 2005 7:00 AM UTC

VRTX said it will discontinue development of merimepodib (MMPD) to focus on VX-702 for rheumatoid arthritis (RA), VX-950 for HCV and a late-stage discovery program for cystic fibrosis (CF). The compa...